Regulation of the p53 protein by the MDM2 oncoprotein - Thirty-eighth G. H. A. Clowes Memorial Award lecture

Cancer Research

Volumn 59, Issue 1, 1999, Pages 1-7

  Freedman, Deborah A ^b   Levine, Arnold J ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; CANCER RESEARCH; CONFERENCE PAPER; DNA DAMAGE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; INTRACELLULAR TRANSPORT; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; TUMOR SUPPRESSOR GENE; ULTRAVIOLET IRRADIATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032893878     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (96)

1. Robb, J. A., Tegtmeyer, P., Ishikawa, A., and Ozer, H. L. Antigenic phenotypes and complementation groups of temperature-sensitive mutants of simian virus 40. J. Virol., 13: 662-665, 1974.
2. Tegtmeyer, P. Function of simian virus 40 gene A in transforming infection. J. Virol., 15: 613-618, 1975.
3. Brugge, J. S., and Butel, J. S. Role of simian virus 40 gene A function in maintenance of transformation. J. Virol., 15: 619-635, 1975.
4. Fried, M. Cell-transforming ability of a temperature-sensitive mutant of polyoma virus. Proc. Natl. Acad. Sci. USA, 53: 486-491, 1965.
5. Tegtmeyer, P., Schwartz, M., Collins, J. K., and Rundell, K. Regulation of tumor antigen synthesis by simian virus 40 gene A. J. Virol., 16: 168-178, 1975.
6. Linzer, D. I. H., and Levine, A. J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell, 17: 43-52, 1979.
7. Lane, D. P., and Crawford, L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature (Lond.), 278: 261-263, 1979.
8. Oren, M., and Levine, A. J. Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. Proc. Natl. Acad. Sci. USA, 80: 56-59, 1983.
9. Pennica, D., Goeddel, D. V., Hayflick, J. S., Reich, N. C., Anderson, C. W., and Levine, A. J. The amino acid sequence of murine p53 determined from a c-DNA clone. Virology, 134: 477-482, 1984.
10. Hinds, P., Finlay, C., and Levine, A. J. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol., 63: 739-746, 1989.
11. Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., White, R., and Vogelstein, B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (Washington DC), 244: 217-221, 1989.
12. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C. C., and Vogelstein, B. Mutations in the p53 gene occur in diverse human tumour types. Nature (Lond.), 342: 705-708, 1989.
13. Finlay, C. A., Hinds, P. W., and Levine, A. J. The p53 proto-oncogene can act as a suppressor of transformation. Cell, 57: 1083-1093, 1989.
14. Bartek, J., Bartkova, J., Vojtesek, B., Staskova, Z., Lukas, J., Rejthar, A., Kovarik, J., Midgley, C. A., Gannon, J. V., and Lane, D. P. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene, 6: 1699-1703, 1991.
15. Li, F. P., Fraumeni, J. F. J., Mulvihill, J. J., Blattner, W. A., Dreyfus, M. G., Tucker, M. A., and Miller, R. W. A cancer family syndrome in twenty-four kindreds. Cancer Res., 48: 5358-5362, 1988.
16. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F. J., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., and Friend, S. H. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (Washington DC), 250: 1233-1238, 1990.
17. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A. J., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356: 215-221, 1992.
18. Harvey, D. M., and Levine, A. J. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev., 5: 2375-2385, 1991.
19. Baker, S. J. Markowitz, S., Fearon, E. R., Willson, J. K. V., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
20. Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A. Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., Vogelstein, B., and Friend, S. H. p53 functions as a cell cycle control protein in osteosarcoma. Mol. Cell. Biol., 10: 5772-5781, 1990.
21. Martinez, J., Georgoff, I., Martinez, J., and Levine, A. J. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev., 5: 151-159, 1991.
22. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.
23. Wu, X., and Levine, A. J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA, 91: 3602-3606, 1994.
24. wafl/cipl. Genes Dev., 8: 2817-2830, 1994.
25. Sabbatini, P., Lin, J., Levine, A. J., and White, E. Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev., 9: 2184-2192, 1995.
26. Haupt, Y., Rowan, S., Shaulian, E., Vousden, K. H., and Oren, M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev., 9: 2170-2183, 1995.
27. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
28. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
29. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
30. Maltzman, W., and Czyzyk, L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol., 4: 1689-1694, 1984.
31. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAFl, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
32. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human box gene. Cell, 80: 293-299, 1995.
33. Okamoto, K., and Beach, D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J., 13: 4816-4822, 1994.
34. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
35. Walker, K. K., and Levine, A. J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA, 93: 15335-15340, 1996.
36. Cahilly-Snyder, L., Yang-Feng, T., Francke, U., and George, D. L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cell Mol. Gene., 13: 235-244, 1987.
37. Fakharzadeh, S. S., Trusko, S. P., and George, D. L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J., 10: 1565-1569, 1991.
38. Wu, X., Bayle, J. H., Olson, D., and Levine, A. J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 7: 1126-1132, 1993.
39. Barak, Y., Juven, T., Haffner, R., and Oren, M. mdm2 expression is induced by wild type p53 activity. EMBO J., 12: 461-468, 1993.
40. Barak, Y., Gottlieb, E., Juven-Gershon, T., and Oren, M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev., 8: 1739-1749, 1994.
41. Perry, M. E., Piette, J., Zawadzki, J. A., Harvey, D., and Levine, A. J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl. Acad. Sci. USA, 90: 11623-11627, 1993.
42. Chen, J., Marechal, V., and Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol., 13: 4107-4114, 1993.
43. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
44. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (Lond.), 362: 857-860, 1993.
45. Chen, J., Lin, J., and Levine, A. J. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med., 1: 142-152, 1995.
46. 1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol., 16: 2445-2452, 1996.
47. Lu, H., and Levine, A. J. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. USA, 92: 5154-5158, 1995.
48. Thut, C. J., Chen, J-L., Klemm, R., and Tjian, R. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science (Washington DC), 267: 100-104, 1995.
49. Thut, C. J., Goodrich, J. A., and Tjian, R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev., 11: 1974-1986, 1997.
50. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. Mdm2 promotes the rapid degradation of p53. Nature (Lond.), 387: 296-299, 1997.
51. Kubbutat, M. H. G., Jones, S. N., and Vousden, K. H. Regulation of p53 stability by Mdm2. Nature (Lond.), 387: 299-303, 1997.
52. Jones, S. N., Roe, A. E., Donehower, L. A., and Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature (Lond.), 378: 206-208, 1995.
53. Montes de Oca Luna, R., Wagner, D. S., and Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (Lond.), 378: 203-206, 1995.
54. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (Lond.), 358: 80-83, 1992.
55. Bueso-Ramos, C. E., Yang, Y., deLeon, E., McCown, P., Stass, S. A., and Albitar, M. The human MDM-2 oncogene is overexpressed in leukemias. Blood, 82: 2617-2623, 1993.
56. Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E. E., and Collins, V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res., 53: 2736-2739, 1993.
57. Ladanyi, M., Cha, C., Lewis, R., Jhanwar, S. C., Huvos, A. G., and Healey, J. H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res., 53: 16-18, 1993.
58. Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W., and Vogelstein, B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res., 53: 2231-2234, 1993.
59. Watanabe, T., Hotta, T., Ichikawa, A., Kinoshita, T., Nagai, H., Uchida, T., Murate, T., and Saito, H. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood, 84: 3158-3165, 1994.
60. Landers, J. E., Haines, D. S., Strauss, J. F., and George, D. L. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene, 9: 2745-2750, 1994.
61. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M. Brennan, M. F., Marechal, V. Chen, J., and Levine, A. J. Molecular abnormalities of mdm-2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54: 794-799, 1994.
62. Forus, A., Florenes, V. A., Maelandsmo, G. M., Fodstad, O., and Myklebost, O. The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas. Cancer Genet. Cytogenet., 78: 165-171, 1994.
63. Landers, J. E., Cassel, S. L., and George, D. L. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res., 57: 3562-3568, 1997.
64. Wu, L., and Levine, A. J. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol. Med., 3: 441-451, 1997.
65. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., and Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (Washington DC), 274: 948-953, 1996.
66. Freedman, D. A., Epstein, C. B., Roth, J. C., and Levine, A. J. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol. Med., 3: 248-259, 1997.
67. Lin, J., Chen, J., Elenbaas, B., and Levine, A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev., 8: 1235-1246, 1994.
68. Roth, J., Dobbelstein, M., Freedman, D. A., Shenk, T., and Levine, A. J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J., 17: 554-564, 1998.
69. Freedman, D. A., and Levine, A. J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol., 18: 7288-7293, 1998.
70. Wen, W., Meinkoth, J. L., Tsien, R. Y., and Taylor, S. S. Identification of a signal for rapid export of proteins from the nucleus. Cell, 82: 463-473, 1995.
71. Fischer, U., Huber, J., Boelens, W. C., Mattaj, I. W., and Luhrmann, R. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell, 82: 475-483, 1995.
72. Palmeri, D., and Malim, M. H. The human T-cell leukemia virus type 1 posttranscriptional trans-activator Rex contains a nuclear export signal. J. Virol., 70: 6442-6445, 1996.
73. Fridell, R. A., Fischer, U., Luhrmann, R., Meyer, B. E., Meinkoth, J. L., Malim, M. H., and Cullen, B. R. Amphibian transcription factor IIIA proteins contain a sequence element functionally equivalent to the nuclear export signal of human immunodeficiency virus type 1 Rev. Proc. Natl. Acad. Sci. USA, 93: 2936-2940, 1996.
74. Murphy, R., and Wente, S. R. An RNA-export mediator with an essential nuclear export signal. Nature (Lond.), 383: 357-360, 1996.
75. Fornerod, M., Ohno, M., Yoshida, M., and Mattaj, I. W. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell, 90: 1051-1060, 1997.
76. Fukuda, M., Asano, S., Nakamura, T., Adachi, M., Yoshida, M., Yanagida, M., and Nishida, E. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature (Lond.), 390: 308-311, 1997.
77. Ossareh-Nazari, B., Bachelerie, F., and Dargemont, C. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science (Washington DC), 278: 141-144, 1997.
78. Bottger, A., Bottger, V., Sparks, A., Liu, W-L., Howard, S. F., and Lane, D. P. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol., 7: 860-869, 1997.
79. Blaydes, J. P., Gire, V., Rowson, J. M., and Wynford-Thomas, D. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2. Oncogene, 14: 1859-1868, 1997.
80. Shieh, S-Y., Ikeda, M., Taya, Y., and Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell, 91: 325-334, 1997.
81. Chen, L., Agrawal, S., Zhou, W., Zhang, R., and Chen, J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. USA, 95, 195-200, 1998.
82. Lu, H., Taya, Y., Ikeda, M., and Levine, A. J. Ultraviolet radiation, but not γ radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc. Natl. Acad. Sci. USA, 95: 6399-6402, 1998.
83. Hupp, T. R., and Lane, D. P. Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. Cold Spring Harbor Symp. Quant. Biol., 59: 195-206, 1994.
84. Hao, M., Lowy, A. M., Kapoor, M., Deffie, A., Liu, G., and Lozano, G. Mutation of phosphoserine 389 affects p53 function in vivo. J. Biol. Chem., 271: 29380-29385, 1996.
85. Ko, L. J., Shieh, S. Y., Chen, X., Jayaraman, L., Tamai, K., Taya, Y., Prives, C., and Pan, Z. Q. p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol. Cell. Biol., 17: 7220-7229, 1997.
86. Jayaraman, L., Murthy, K. G. K., Zhu, C., Curran, T., Xanthoudakis, S., and Prives, C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev., 11: 558-570, 1997.
87. Gu, W., and Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell, 90: 595-606, 1997.
88. Sakaguchi, K., Herrera, J. E., Saito, S. I., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., and Appella, E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev., 12: 2831-2841, 1998.
89. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723, 1998.
90. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92: 725-734, 1998.
91. Lutzker, S. G., and Levine, A. J. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat. Med., 2: 804-810, 1996.
92. Schuler, M., Rochlitz, C., Horowitz, J. A., Schlegel, J., Perruchoud, A. P., Kommoss, F., Bollinger, C. T., Kauczor, H-U., Dalquen, P., Fritz, M. A., Swanson, S., Herrmann, R., and Huber, C. A Phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum. Gene Ther., 9: 2075-2082, 1998.
93. Sheikh, M. S., Shao, Z-M., Hussain, A., and Fontana, J. A. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res., 53: 3226-3228, 1993.
94. He, J., Reifenberger, G., Liu, L., Collins, V. P., and James, C. D. Analysis of glioma cell lines for amplification and overexpression of MDM2. Genes Chromosomes Cancer, 11: 91-96, 1994.
95. Corvi, R., Savelyeva, L., Breit, S., Wenzel, A., Handgretinger, R., Barak, J., Oren, M., Amler, L., and Schwab, M. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene, 10: 1081-1086, 1995.
96. Keleti, J., Quezado, M. M., Abaza, M. M., Raffeld, M., and Tsokos, M. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am. J. Pathol., 149: 143-151, 1996.